EMA's regular press briefing on #PublicHealth emergencies https://n.respublicae.eu/i/broadcasts/1PlJQpdZXqXGE
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603691539594907648
At the end of 2022, we have:
🔶7 #COVID19vaccines
🔶4 #AdaptedVaccines that target several variants of the virus
🔶vaccines for children from 6 months of age, particularly those with underlying conditions
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603692024573607939
It is likely that we will have to update the #COVID19vaccines regularly to offer re-vaccination to vulnerable groups, as we do with the #Influenza vaccine. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603692179645415424
The virus is here to stay 🦠. We will have to prudently move towards a new normal, making the best use of the tools that can protect us, starting from vaccines 💉. #EMAPresser #VaccineWork
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603692342283845633
The data suggest that primary vaccination with #AdaptedVaccines should give rise to a broad immune response in people who have not yet been exposed to, or vaccinated against, #COVID19.
#EMAPresser ⬇️
?s=20&t=KqADz96VvID1BBfuQsfSMw
RT @EMA_News: EMA concludes that adapted mRNA #COVID19vaccines targeting the original strain and Omicron BA.4-5 subvariants of the SARS-CoV-2 virus may be used for initial vaccination.
These #AdaptedVaccines are currently only authoris…
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603692963514777601
🔍The data show that the #safety profile of the adapted vaccines, when used as #boosters, is comparable to that of the original mRNA vaccines, for which the safety profile is well established.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603693131391795200
📢 Yesterday, EMA met with @US_FDA to define development pathways that could allow timely approval of the next generation of monoclonal antibodies. #EMAPresser
?s=20&t=I6LVdO32Vg-kMlOAiyk6Pg
RT @EMA_News: 📢Our Emergency Task Force warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2. Read the full statement 👇
https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2
#COVID19 #PublicHealth
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603693624721637376
#Influenza season epidemic kicks off early in Europe as concerns over #RSV rise and #COVID19 remains a threat.
‼️ There is a high risk that the co-circulation of these diseases will place pressure on healthcare systems in the coming weeks. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603693860542205952
❗️It is extremely important that elderly people, pregnant persons and immunocompromised patients get re-vaccinated against #influenza and #COVID19.
Vaccines that combine #flu and COVID are under development. They could simplify vaccination campaigns in the future. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603694437619695621
This autumn, EMA became the 1st regulator in the 🌍 to approve #Beyfortus, a monoclonal antibody to prevent serious lower respiratory tract disease caused by #RSV in newborns & children. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1603694029446725635